Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease Kadoaki Ohashi , Yosef E. Maruvka , Franziska Michor , William Pao Journal of Clinical Oncology 2013 31: 8 , 1070-1080 ...

Epidermal growth factor receptor (EGFR) is a protein tyrosine kinase which plays a crucial role in signal transduction pathways that regulate key cellular functions such as survival and proliferation.

Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?. JCO 35 , 3089-3091 (2017). DOI: ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

The epidermal growth factor receptor (EGFR) is a target found in high concentrations in several solid tumors including lung, breast, colorectal, and brain. Tyrosine kinase inhibitors, such as ...

Epidermal growth factor receptor, also known as EGFR, is a biomarker frequently implicated in cancer and EGFR-TKIs are a class of drugs commonly used to target EGFR and treat the disease.

Activity Description. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant ...

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been found to have varying degrees of cardiotoxic risks that should be applied to clinical practice ...

In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had received one ...